# A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

> **NCT04492436** · PHASE2 · WITHDRAWN · sponsor: **Veloxis Pharmaceuticals**

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** thrombomodulin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04492436
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2023-04
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study design was changed
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492436, "A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04492436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*